Integrated PTSD and Chronic Pain Treatment

This study is testing a new approach to help people who experience both post-traumatic stress disorder (PTSD) and chronic pain. It uses a treatment called "Integrated Treatment for PTSD and Chronic Pain," which combines parts of two proven therapies: Prolonged Exposure (for PTSD) and Cognitive Behavioral Therapy for Chronic Pain. The treatment involves 12 virtual therapy sessions, each 90 minutes long, twice a week. Researchers want to see how many people are interested, how many join, and how many sessions they attend. You might be able to join if you are 18 or older, speak English, have both PTSD and chronic pain (pain severity of 4 or more out of 10 for at least 3 months), and are medically stable. This study is currently recruiting about 20 participants.

Study design
This study is an interventional study with a planned enrollment of 20 participants. It is not specified if it is randomized or blinded.
What's involved
You would participate in 12 virtual psychotherapy sessions, each 90 minutes long, scheduled twice per week. These sessions would last for approximately 6 weeks.
Compensation
Not stated in the trial record.
Follow-up
The study measures session attendance at approximately 6 weeks, which is the post-treatment assessment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07225049

Integrated PTSD and Chronic Pain Treatment

Recruiting
NAAges 18+InterventionalTreatment
Weill Medical College of Cornell University
~20 participants
Updated 2026-06-15 on ClinicalTrials.gov
What's tested:Integrated Treatment for PTSD and Chronic Pain

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Feasibility Indicator: Number of Participants Screened
Measured over Baseline
+8 more outcomes measured
PTSD
Chronic Pain
1 sites across 1 states
New York1
  • JoAnn Difede, PhD · PRINCIPAL_INVESTIGATOR · Weill Medical College of Cornell University

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18 years or older
English-speaking
Currently meets criteria for PTSD, assessed by the CAPS-5 (any trauma type) - Chronic pain, assessed by greater than or equal to 4 on a scale of 0-10 pain severity over the past 3 months
Medically stable at the time of study enrollment (chronic illness and disability does not prevent attendance of outpatient therapy sessions)
Stable on psychotropic medication for past 60 days
Agreed to not change current medication or pain-related treatments over the course of the study unless medically necessary
Must be located in the state of New York for virtual assessments and treatment sessions

Exclusion

Lifetime diagnosis of schizophrenia, other psychotic disorder, or bipolar I disorder
Participation in concurrent evidence-based psychological treatment for PTSD or chronic pain during the past 3 months
Participants must not participate in an evidence-based psychological treatment for either PTSD or pain during the course of the study.
Moderate or severe substance use in the past 90 days
Cognitive impairment to the degree that the patient cannot provide informed consent or fill out assessment measures
Participants who in the PI's judgement pose a current homicidal or suicidal risk
  • Feasibility Indicator: Number of Participants ScreenedBaseline

    Feasibility assessment will include number of participants screened defined as number of individuals who complete our initial eligibility screener.

  • Feasibility Indicator: EnrollmentBaseline

    Feasibility assessment will include enrollment defined as number of participants signing the informed consent form.

  • Feasibility Indicator: Number of Sessions AttendedPost-Treatment Assessment at approximately 6 weeks

    Feasibility assessment will include the number of sessions attended on average (out of 12).

  • Feasibility Indicator: Attrition PercentagePost-Treatment Assessment at approximately 6 weeks

    A feasibility measure of attrition will be assessed by examining the percent of individuals who did not complete all 12 intervention sessions.

  • Feasibility Indicator: Number of Assessments AttendedBaseline and Post-Treatment Assessment at approximately 6 weeks

    A feasibility indicator of number of assessments (baseline and post-treatment) attended will be measured.

  • Feasibility Indicator: Percentage of Self-Reports CompletedBaseline, Post-Intervention at approximately 6 weeks, Every Other Treatment Session (Every 2 weeks up to 12 weeks)

    Self-reports are administered at each assessment (baseline and post-intervention) as well as every other treatment session (every 2 weeks up to 12 weeks). Therefore, there are 8 total self-report assessments and the percentage of those completed will be calculated.

  • Intervention SatisfactionPost-Treatment Assessment at approximately 6 weeks

    Intervention satisfaction will be rated with a Likert scale ranging from 1-10 with greater scores indicating higher satisfaction.

  • Intervention AcceptabilityPost-Treatment Assessment at approximately 6 weeks

    Intervention acceptability will be measured on a Likert scale ranging from 1-10 with greater scores indicating higher acceptability.

  • Qualitative Intervention FeedbackPost-Treatment Assessment at approximately 6 weeks

    Open-ended questions that include assessing overall impressions of treatment, feedback on the frequency and length of sessions, challenges or barriers, likelihood of recommending this treatment to a friend, and comparison of this treatment to other treatments received in the past.